NOW® Sports Organic Pea Protein is a non-GMO vegetable protein isolate that has 15 grams of easily-digested protein. Each 2 scoop serving typically has over 2,700 mg of branched-chain amino acids, and over 1,300 mg of arginine. NOW® Sports Organic Pea Protein is pure and natural, unflavored, and mixes easily into your favorite beverages.

Studies indicate that pea protein has the potential of lowering eye pressure naturally and may have neuroprotective properties - see below for more information.

Natural color variation may occur in this product.

This product is sold by weight not volume.

Cerified Organic by QAI.

• Pure Unflavored
• 15 G Protein

Product Info:
Serving Size: 1 Scoop
Servings Per Container: 27
Amount Per Serving: Calories 120
Total Fat 2 g 3%
Trans Fat 0 g
Cholesterol 0 mg
Sodium 320 mg 14%
Total Carbohydrate 1 g
Dietary Fiber 0 g
Total Sugars 0 g
Includes 0 g Added Sugars
Protein 24 g 48%
Vit. D 0 mcg 0%
Calcium 43 mg 4%
Iron 8 mg 45%
Potas. 83 mg 2%

Dietary Considerations: This vegetarian/vegan formula is Kosher and free of the following: wheat, dairy/milk, soy, gluten, egg, corn, starch, yeast, preservatives, shellfish and other fish, and tree nuts. It is GMO free as well.

Suggested Use: Add 1 level scoop daily to 12 oz. of cold water, juice, or your favorite beverage and blend.Ingredient: yellow pea protein isolate

Warnings: Use this product as a food supplement only. Do not use for weight reduction. Store in a cool, dry place. This product is sold by weight not volume.

A recent clinical trial adds to evidence that oral intake of palmitoylethanolamide (PEA) improves glaucoma scores alongside prescription eye drops. 1

In the trial, PEA lowered damaging eye pressure in glaucoma patients and led to improvements on tests of retinal function.

PEA improves the outflow or drainage of the aqueous humor, reducing fluid levels. 2,3 Human studies have shown that oral intake of 600 mg of PEA daily significantly lowers intraocular pressure. 2,3

In one randomized, placebo-controlled study, 300 mg of PEA twice per day for three months resulted in reduced intraocular pressure and improved endothelial function (measured by flow-mediated dilation). 4

In addition, animal studies show that PEA has neuroprotective effects, shielding nerve cells in the retina and the brain from damage due to various forms of injury. 5-8

Researchers in Italy recently conducted a clinical trial of PEA in glaucoma patients. 1

People who were already taking eye-drop medications for glaucoma were randomized into two groups. One continued the current therapy. The second group also took 600 mg of PEA daily. 1

A non-invasive test called a pattern electroretinogram (PERG) was performed on all subjects. This measures eye health by testing the function of the retinal ganglion cells that are damaged by glaucoma. 9,10

At the end of the study, patients who took PEA had PERG test scores that were approximately 43% improved compared to their starting values and the values of subjects who did not receive PEA.

The intraocular pressure of all subjects was also recorded. Those taking PEA had significantly lower eye intraocular pressure, (an average reduction of about 1.58 points). 1

Study References:

1. Yazulla S. Endocannabinoids in the retina: from marijuana to neuroprotection. Prog Retin Eye Res. 2008 Sep;27(5): 501-26.
2. Gagliano C, Ortisi E, Pulvirenti L, et al. Ocular hypotensive effect of oral palmitoyl-ethanolamide: a clinical trial. Invest Ophthalmol Vis Sci. 2011 Aug 3;52(9):6096-100.
3. Pescosolido N, Librando A, Puzzono M, et al. Palmitoylethanolamide effects on intraocular pressure after Nd:YAG laser iridotomy: an experimental clinical study. J Ocul Pharmacol Ther. 2011 Dec;27(6): 629-35.
4. Strobbe E, Cellini M, Campos EC. Effectiveness of palmitoylethanolamide on endothelial dysfunction in ocular hypertensive patients: a randomized, placebo-controlled cross-over study. Invest Ophthalmol Vis Sci. 2013 Feb 1;54(2):968-73.
5. Levkovitch-Verbin H. Retinal ganglion cell apoptotic pathway in glaucoma: Initiating and downstream mechanisms. Prog Brain Res. 2015;220:37-57.
6. Nucci C, Gasperi V, Tartaglione R, et al. Involvement of the endocannabinoid system in retinal damage after high intraocular pressure-induced ischemia in rats. Invest Ophthalmol Vis Sci. 2007 Jul;48(7):2997-3004.
7. Rapino C, Tortolani D, Scipioni L, et al. Neuroprotection by (endo)Cannabinoids in Glaucoma and Retinal Neurodegenerative Diseases. Curr Neuropharmacol. 2018;16(7):959-70.
8. Yazulla S. Endocannabinoids in the retina: from marijuana to neuroprotection. Prog Retin Eye Res. 2008 Sep;27(5): 501-26. 9. Falsini B, Marangoni D, Salgarello T, et al. Structure-function relationship in ocular hypertension and glaucoma: interindividual and interocular analysis by OCT and pattern ERG. Graefes Arch Clin Exp Ophthalmol. 2008 Aug;246(8):1153-62.
10. Graham SL, Drance SM, Chauhan BC, et al. Comparison of psychophysical and electrophysiological testing in early glaucoma. Invest Ophthalmol Vis Sci. 1996 Dec;37(13):2651-62.